Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)

Neurotherapeutics

Volumn 11, Issue 2, 2014, Pages 358-372

  Kanner, Andres M ^a   Mazarati, Andrey ^b   Koepp, Matthias ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

GABA; Glutamate; Hypothalamic pituitary adrenal axis; Major depressive disorder; Opioids; Selective serotonin reuptake inhibitors; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; BIOLOGICAL MARKER; GLUTAMIC ACID; NEUROTRANSMITTER; OPIATE; OPIATE RECEPTOR; SEROTONIN;

CENTRAL NERVOUS SYSTEM; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENCEPHALITIS; EPILEPSY; EPILEPTOGENESIS; EXPERIMENTAL STUDY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; MOOD DISORDER; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE; SEROTONINERGIC TRANSMISSION; ANIMAL; MENTAL DISORDERS; PATHOPHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; COMORBIDITY; EPILEPSY; HUMANS; MENTAL DISORDERS;

EID: 84899478829     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0271-4     Document Type: Review

References (193)

1. Forsgren L, Nystrom L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res 1990;6: 66-81.
2. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000;47: 246-249.
3. Hesdorffer DC, Hauser WA, Ludvigsson P, Olafsson E, Kjartansson O. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol 2006;59: 35-41.
4. Hesdorffer DC, Ludvigsson P, Olafsson E, Gudmundsson G, Kjartansson O, Hauser WA. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004;61: 731-736.
5. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012;72: 184-191.
6. Adelow C, Anderson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012;78: 396-401.
7. Chang YT, Chen PC, Tsai IJ, et al. Bidirectional relation between schizophrenia and epilepsy: A population-based retrospective cohort study. Epilepsia 2011;52: 2036-2042.
8. Alper KR, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62: 345-354.
9. Favale E, Audenino D, Cocito L, Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 2003;12: 316-318.
10. Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004;27: 133-136.
11. Favale E, RubinoV, Mainardi P, Lunardi G, Albano C. The anticonvulsant effect of fluoxetine in humans. Neurology 1995;45: 1926.
12. Clinckers R, Smolders I, Meurs A, et al. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D2 and 5-HT1A receptors. J Neurochem 2004;89: 834-843.
13. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57: 174-180.
14. Toczek MT, Carson RE, Lang L. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003;60: 749-756.
15. Theodore WH, Giovacchini G, Bonwetsch R. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia 2006: 47: 499-503.
16. Hasler G, Bonwetsch R, Giovacchini G. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007;62: 1258-1264.
17. Merlet I, Ostrowsky K, Costes N, et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain 2004;127: 900-913.
18. Merlet I, Ryvlin P, Costes N, et al. Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. Neuroimage 2004;22: 886-896.
19. Martinez A, Finegersh A, Cannon DM, et al. The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. Neurology 2013;80: 1465-1471.
20. Lothe A, Didelot A, Hammers A, et al. Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study. Brain 2008;131: 2765-2782.
21. Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. J Affect Disord 2013;146: 262-265.
22. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47: 351-354.
23. Zarate CA, Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63: 856-864.
24. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61: 705-713.
25. Peng WF, Ding J, Mao LY, et al. Increased ratio of glutamate/glutamine to creatine in the right hippocampus contributes to depressive symptoms in patients with epilepsy. Epilepsy Behav 2013;29: 144-149.
26. Bonanno G, Giambelli R, Raiteri L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005;25: 3270-3279.
27. Gerner RH, Hare TA. CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry 1981;138: 1098-1101.
28. Sanacora G, Mason GF, Rothman DL, et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 1999;56: 1043-1047.
29. Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002;59: 521-529.
30. Bhagwagar, Z., Wylezinska, M., Jezzard, et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 2007;61: 806-812.
31. Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002;159: 663-665.
32. Sanacora G, Mason GF, Rothman DL, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003;160: 577-579.
33. Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol 1993;471: 501-519.
34. Davies CH, Davies SN, Collingridge GL. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. J Physiol 1990;424: 513-531.
35. Bajbouj M, Lisanby SH, Lang UE, Danker-Hopfe H, Heuser I, Neu P. Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol Psychiatry 2006;59: 395-400.
36. Lefaucheur JP, Lucas B, Andraud F, et al. Inter-hemispheric asymmetry of motor corticospinal excitability in major depression studied by transcranial magnetic stimulation. J Psychiatr Res 2008;42: 389-398.
37. Levinson AJ, Fitzgerald PB, Favallli G, Blumberger DM, Daigle M, Daskalakis ZJ. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 2010;67: 458-464.
38. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ. Neurobiology of depression. Neuron 2002;34: 1325.
39. Zobel A, Wellmer J, Schulze-Rauschenbach S, et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci 2004;254: 303-311.
40. López JF, Chalmers DT, Little KY, Watson SJ. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998;15;43: 547-573.
41. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000;15;48: 755-765.
42. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002;52: 404-412.
43. Öngür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998;95: 13290-13295.
44. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999;45: 1085-1098.
45. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001;58: 545-553.
46. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002;12: 386-394.
47. Crossin KL, Tai MH, Krushel LA, Mauro VP, Edelman GM. Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Proc Natl Acad Sci U S A 1997;94: 2687-2692.
48. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157: 115-118.
49. Bell-McGinty S, Butters MA, Meltzer CC, Greer PJ, Reynolds CF, Becker JT. Brain morphometric abnormalities in geriatric depression: long-term neurobiological effects of illness duration. Am J Psychiatry 2002;159: 1424-1427.
50. Cambell S, Marriott M, Nahmias C, MacQueen G. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004;161: 598-607.
51. Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression Controlled magnetic resonance imaging study. Br J Psychiatry 1998;172: 527-532.
52. Sheline YI, Sanghavi M, Mintun MA, Gado MH. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999: 19: 5034-5043.
53. Shamim S, Hasler G, Liew C, Sato S, Theodore WH Temporal lobe epilepsy, depression, and hippocampal volume. Epilepsia 2009;50: 1067-1071.
54. Tebartz van Elst L, Woermann FG, Lemieux L, Trimble MR. Amygdala enlargement in dysthymia-a volumetric study of patients with temporal lobe epilepsy. Biol Psychiatry 1999;461: 1614-1623.
55. Richardson EJ, Griffith HR, Martin RC, et al. Structural and functional neuroimaging correlates of depression in temporal lobe epilepsy. Epilepsy Behav 2007;10: 242-249.
56. Briellmann RS, Hopwood MJ, Jackson GD. Major depression in temporal lobe epilepsy with hippocampal sclerosis: clinical and imaging correlates. J Neurol Neurosurg Psychiatry 2007;78: 1226-1230.
57. Quiske A, Helmstaedter C, Lux S, Elger CE Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000;39: 121-125.
58. Salgado PC, Yasuda CL, Cendes F. Neuroimaging changes in mesial temporal lobe epilepsy are magnified in the presence of depression. Epilepsy Behav 2010;19: 422-427.
59. Wrench JM, Wilson SJ, Bladin PF, Reutens DC Hippocampal volume and depression: insights from epilepsy surgery. J Neurol Neurosurg Psychiatry 2009;80: 539-544.
60. Adams SJ, O'Brien TJ, Lloyd J, Kilpatrick CJ, Salzberg MR, Velakoulis D. Neuropsychiatric morbidity in focal epilepsy. Br J Psychiatry 2008;192: 464-469.
61. Baxendale SA, Thompson PJ, Duncan JS. Epilepsy and depression: the effects of comorbidity on hippocampal volume-a pilot study. Seizure 2005;14: 435-438.
62. Finegersh A, Avedissian C, Shamim S, Dustin I, Thompson PM, Theodore WH. Bilateral hippocampal atrophy in temporal lobe epilepsy: effect of depressive symptoms and febrile seizures. Epilepsia 2011;52: 689-697.
63. Paparrigopoulos T, Ferentinos P, Brierley B, Shaw P, David AS. Relationship between post-operative depression/anxiety and hippocampal/amygdala volumes in temporal lobectomy for epilepsy. Epilepsy Res 2008;81: 30-35.
64. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. NeuroReport 1998;9: 2023-2028.
65. Bremner JD, Vythilingam M, Vermetten E, et al. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 2002;51: 273-279.
66. Kempton MJ, Salvador Z, Munafò MR, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011;68: 675-690.
67. Arnone D, McIntosh AM, Ebmeier KP, Munafò MR, Anderson IM. Magnetic resonance imaging studies in uni polar depression: systematic review and meta-regression analyses. Eur Neuropsychopharmacol 2012;22: 1-16.
68. Lai CH Gray matter volume in major depressive disorder: a meta-analysis of voxel-based morphometry studies. Psychiatry Res 2013;211: 37-46.
69. Raichle ME, Snyder AZ. A default mode of brain function: a brief history of an evolving idea. Neuroimage 2007;37: 1083-1109.
70. Lin JJ, Salamon N, Lee AD, et al. Reduced neocortical thickness and complexity mapped in mesial temporal lobe epilepsy with hippocampal sclerosis. Cereb Cortex 2007;17: 2007-2018.
71. Bilevicius E, Yasuda CL, Silva MS, Guerreiro CA, Lopes-Cendes I, Cendes F. Antiepileptic drug response in temporal lobe epilepsy: a clinical and MRI morphometry study. Neurology 2010;75: 1695-1701.
72. Bromfield EB, Altshuler L, Leiderman DB, et al. Cerebral metabolism and depression in patients with complex partial seizures. Arch Neurol 1992;49: 617-623.
73. Salzberg M, Taher T, Davie M, et al. Depression in temporal lobe epilepsy surgery patients: an FDG-PET study. Epilepsia 2006;47: 2125-2130.
74. Schmitz EB, Moriarty J, Costa DC, Ring HA, Ell PJ, Trimble MR. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy. J Neurol Neurosurg Psychiatry 1997;62: 458-463.
75. Gilliam FG, Santos J, Vahle V, Carter J, Brown K, Hecimovi H. Depression in epilepsy: ignoring clinical expression of a neuronal network dysfunction? Epilepsia 2004;45(Suppl. 2): 28-33.
76. Gilliam FG, Maton BM, Martin RC, et al. Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy. Neurology 2007;68: 364-368.
77. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004;73: 953-990.
78. Bodkin JA, Zomberg GL, Lukas SE, Cole JO. Buprenorphine treatment in refractory depression. J Clin Pscyhopharmacol 1995;15: 49-57.
79. Gabilondo AM, Meana JJ, Garcia-Sevilla JS. Increased density of mu-opined receptors in the postmortem brain of suicide victims. Brain Res 1995;682: 245-250.
80. Mayberg HS, Dannals RF, Ross CA, et al. Mu opiate receptor binding in depressed patients measured with PET and 11C-carfentanil. J Nucl Med 1991;32: 1078.
81. Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med 1993;23: 579-590.
82. Zubieta JK, Ketter TA, Bueller JA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 2003;60: 1145-1153.
83. Koepp MJ, Hammers A, Lawrence AD, Asselin MC, Grasby PM, Bench CJ. Evidence for endogenous opioid release in the amygdala during positive emotion. Neuroimage 2009;44: 252-256.
84. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science 1986;233: 774-776.
85. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63: 1199-1208.
86. Pfeiffer A, Pasi A, Mehraein P, Herz A. Opiate receptor binding sites in human brain. Brain Res 1982;248: 87-96.
87. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003;305: 323-330.
88. Jutkiewicz EM. The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 2006;6: 162-169.
89. Mayberg HS, Sadzot B, Meltzer CC, et al. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol 1991;30: 3-11.
90. Hammers A, Asselin MC, Hinz R, Kitchen I, Brooks DJ, Duncan JS, Koepp MJ. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 2007;130: 1009-1016.
91. Bremmer MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord 2008;106: 249-255.
92. Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry 2012;83: 495-502.
93. Muller N, Myint AM, Schwarz MJ. Inflammatory biomarkers and depression. Neurotox Res 2011;19: 308-318.
94. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep 2008;10: 258-264.
95. Dantzer R, Kelley KW. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sci 1989;44: 1995-2008.
96. Borkowska P, Kucia K, Rzezniczek S, et al. Interleukin-1beta promoter (-31T/C and -511C/T) polymorphisms in major recurrent depression. J Mol Neurosci 2011;44: 12-16.
97. Baune BT, Dannlowski U, Domschke K, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 2010;67: 543-549.
98. Crespel A, Coubes P, Rousset MC, et al. Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res. 2002;952: 159-169.
99. Ravizza T, Boer K, Redeker S, et al. The Il-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 2006;24: 128-143.
100. Boer K, Jansen F, Nellist M, et al. Inflammatory processes in cortical tubers, and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res 2008;78: 7-21.
101. Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000;7: 153-159.
102. Bezzi P, Domercq M, Brambilla L, et al. A. CXCR4-activated astrocyte glutamate release via TNFalpha: Amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4: 702-710.
103. Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003;23: 8692-8700.
104. Chugani HT, Luat AF, Kumar A, et al. α-[11C]-Methyl-L-tryptophan-PET in 191 patients with tuberous sclerosis complex. Neurology 2013;81: 674-680.
105. Juhász C, Buth A, Chugani DC, et al. Successful surgical treatment of an inflammatory lesion associated with new-onset refractory status epilepticus. Neurosurg Focus 2013;34: E5.
106. Herman JP, Cullinan WE. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997;20: 78-84.
107. Herman JP, Prewitt CM, Cullinan WE. Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Crit Rev Neurobiol 1996;10: 371-394.
108. Yu S, Holsboer F, Almeida OF. Neuronal actions of glucocorticoids: focus on depression. J Steroid Biochem Mol Biol 2008;108: 300-309.
109. Herbert J. Cortisol and depression: three questions for psychiatry. Psychol Med 2013;43: 449-469.
110. Chaouloff F. Serotonin, stress and corticoids. J Psychopharmacol 2000;14: 139-151.
111. Dinan T. Novel approaches to the treatment of depression by modulating the hypothalamic - pituitary - adrenal axis. Hum Psychopharmacol 2001;16: 89-93.
112. Aisa B, Tordera R, Lasheras B, Del Rio J, Ramirez MJ. Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology 2007;32: 256-266.
113. Liberzon I, Krstov M, Young EA. Stress-restress: effects on ACTH and fast feedback. Psychoneuroendocrinology 1997;22: 443-453.
114. Edwards E, King JA, Fray JC. Increased basal activity of the HPA axis and renin-angiotensin system in congenital learned helpless rats exposed to stress early in development. Int J Dev Neurosci 1999;17: 805-812.
115. Novati A, Roman V, Cetin T, et al. Chronically restricted sleep leads to depression-like changes in neurotransmitter receptor sensitivity and neuroendocrine stress reactivity in rats. Sleep 2008;31: 1579-1585.
116. Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH. The dex/CRH test-is it better than the DST? Psychoneuroendocrinology 2006;31: 889-894.
117. Holmes PV. Rodent models of depression: reexamining validity without anthropomorphic inference. Crit Rev Neurobiol 2003;15: 143-174.
118. Richardson JS. Animal models of depression reflect changing views on the essence and etiology of depressive disorders in humans. Prog Neuropsychopharmacol Biol Psychiatry 1991;15: 199-204.
119. Gregus A, Wintink AJ, Davis AC, Kalynchuk LE. Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav Brain Res 2005;156: 105-114.
120. Johnson SA, Fournier NM, Kalynchuk LE. Effect of different doses of corticosterone on depression-like behavior and HPA axis responses to a novel stressor. Behav Brain Res 2006;168: 280-288.
121. El Yacoubi M, Bouali S, Popa D, et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci U S A 2003;100: 6227-6232.
122. Jones NC, Lee HE, Yang M, et al. Repeatedly stressed rats have enhanced vulnerability to amygdala kindling epileptogenesis. Psychoneuroendocrinology 2013;38: 263-270.
123. Kumar G, Jones NC, Morris MJ, Rees S, O'Brien TJ, Salzberg MR. Early life stress enhancement of limbic epileptogenesis in adult rats: mechanistic insights. PLoS One 2011;6: e24033.
124. Lai MC, Holmes GL, Lee KH, et al. Effect of neonatal isolation on outcome following neonatal seizures in rats--the role of corticosterone. Epilepsy Res 2006;68: 123-136.
125. Karst H, de Kloet ER, Joels M. Episodic corticosterone treatment accelerates kindling epileptogenesis and triggers long-term changes in hippocampal CA1 cells, in the fully kindled state. Eur J Neurosci 1999;11: 889-898.
126. Taher TR, Salzberg M, Morris MJ, Rees S, O'Brien TJ. Chronic low-dose corticosterone supplementation enhances acquired epileptogenesis in the rat amygdala kindling model of TLE. Neuropsychopharmacology 2005;30: 1610-1616.
127. Kumar G, Couper A, O'Brien TJ, et al. The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology 2007;32: 834-842.
128. Talmi M, Carlier E, Bengelloun W, Soumireu-Mourat B. Synergistic action of corticosterone on kainic acid-induced electrophysiological alterations in the hippocampus. Brain Res 1995;704: 97-102.
129. Castro OW, Santos VR, Pun RY, et al. Impact of corticosterone treatment on spontaneous seizure frequency and epileptiform activity in mice with chronic epilepsy. PLoS One 2012;7: e46044.
130. Kent S, Kernahan SD, Levine S. Effects of excitatory amino acids on the hypothalamic-pituitary-adrenal axis of the neonatal rat. Brain Res Dev Brain Res 1996;94: 1-13.
131. Chautard T, Boudouresque F, Guillaume V, Oliver C. Effect of excitatory amino acid on the hypothalamo-pituitary-adrenal axis in the rat during the stress-hyporesponsive period. Neuroendocrinology 1993;57: 70-78.
132. Daniels WM, Jaffer A, Engelbrecht AH, Russell VA, Taljaard JJ. The effect of intrahippocampal injection of kainic acid on corticosterone release in rats. Neurochem Res 1990;15: 495-499.
133. Mazarati AM, Shin D, Kwon YS, et al. Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis 2009;34: 457-461.
134. Inostroza M, Cid E, Menendez de la Prida L, Sandi C. Different emotional disturbances in two experimental models of temporal lobe epilepsy in rats. PLoS One 2012;7: e38959.
135. Kharatishvili I, Pitkanen A. Association of the severity of cortical damage with the occurrence of spontaneous seizures and hyperexcitability in an animal model of posttraumatic epilepsy. Epilepsy Res 2010;90: 47-59.
136. Kharatishvili I, Nissinen JP, McIntosh TK, Pitkanen A. A model of posttraumatic epilepsy induced by lateral fluid-percussion brain injury in rats. Neuroscience 2006;140: 685-697.
137. Griesbach GS, Hovda DA, Tio DL, Taylor AN. Heightening of the stress response during the first weeks after a mild traumatic brain injury. Neuroscience 2011;178: 147-158.
138. Shultz SR, Bao F, Omana V, Chiu C, Brown A, Cain DP. Repeated mild lateral fluid percussion brain injury in the rat causes cumulative long-term behavioral impairments, neuroinflammation, and cortical loss in an animal model of repeated concussion. J Neurotrauma 2012;29: 281-294.
139. Pandey DK, Yadav SK, Mahesh R, Rajkumar R. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety? Behav Brain Res 2009;205: 436-442.
140. Kuo JR, Cheng YH, Chen YS, Chio CC, Gean PW. Involvement of extracellular signal regulated kinases in traumatic brain injury-induced depression in rodents. J Neurotrauma 2013;30: 1223-1231.
141. Aghajanian GK, Sprouse JS, Sheldon P, Rasmussen K. Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. Ann N Y Acad Sci 1990;600: 93-103.
142. Riad M, Garcia S, Watkins KC, et al. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 2000;417: 181-194.
143. Richardson-Jones JW, Craige CP, Guiard BP, et al. 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010;65: 40-52.
144. Mazarati AM, Pineda E, Shin D, Tio D, Taylor AN, Sankar R. Comorbidity between epilepsy and depression: role of hippocampal interleukin-1beta. Neurobiol Dis 2010;37: 461-467.
145. Zhou J, Cao X, Mar AC, et al. Activation of postsynaptic 5-HT receptors improve stress adaptation. Psychopharmacology 2013 Nov 21 [Epub ahead of print].
146. De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol 2004;14: 487-495.
147. Llado-Pelfort L, Assie MB, Newman-Tancredi A, Artigas F, Celada P. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br J Pharmacol 2010;160: 1929-1940.
148. Siegel J, Murphy GJ. Serotonergic inhibition of amygdala-kindled seizures in cats. Brain Res 1979;174: 337-340.
149. Hernandez EJ, Williams PA, Dudek FE. Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. Epilepsia 2002;43: 1337-1345.
150. Mazarati A, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008;131: 2071-2083.
151. Vermoesen K, Massie A, Smolders I, Clinckers R. The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy. Epilepsia 2012;53: 870-878.
152. Mazarati AM, Baldwin RA, Shinmei S, Sankar R. In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures. J Neurochem 2005;95: 1495-1503.
153. Salgado D, Alkadhi KA. Inhibition of epileptiform activity by serotonin in rat CA1 neurons. Brain Res 1995;669: 176-182.
154. Lu KT, Gean PW. Endogenous serotonin inhibits epileptiform activity in rat hippocampal CA1 neurons via 5-hydroxytryptamine1A receptor activation. Neuroscience 1998;86: 729-737.
155. Salgado-Commissariat D, Alkadhi KA. Serotonin inhibits epileptiform discharge by activation of 5-HT1A receptors in CA1 pyramidal neurons. Neuropharmacology 1997;36: 1705-1712.
156. Tokarski K, Zahorodna A, Bobula B, Hess G. Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat hippocampus. Exp Brain Res 2002;147: 505-510.
157. Lopez-Meraz ML, Martinez A, Rocha L. Effect of 8-OH-DPAT on electrographic activity during the kainic acid-induced status epilepticus in rats. Seizure 2007;16: 365-370.
158. Gariboldi M, Tutka P, Samanin R, Vezzani A. Stimulation of 5-HT1A receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. Br J Pharmacol 1996;119: 813-818.
159. Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, Toth M. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A 2000;97: 14731-14736.
160. Statnick MA, Dailey JW, Jobe PC, Browning RA. Abnormalities in brain serotonin concentration, high-affinity uptake, and tryptophan hydroxylase activity in severe-seizure genetically epilepsy-prone rats. Epilepsia 1996;37: 311-321.
161. Statnick MA, Dailey JW, Jobe PC, Browning RA. Abnormalities in 5-HT1A and 5-HT1B receptor binding in severe-seizure genetically epilepsy-prone rats (GEPR-9s). Neuropharmacology 1996;35: 111-118.
162. Dailey JW, Mishra PK, Ko KH, Penny JE, Jobe PC. Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats. Life Sci 1992;50: 319-326.
163. Pineda EA, Hensler JG, Sankar R, Shin D, Burke TF, Mazarati AM. Plasticity of presynaptic and postsynaptic serotonin 1A receptors in an animal model of epilepsy-associated depression. Neuropsychopharmacology 2011;36: 1305-1316.
164. Bellido I, Hansson AC, Gomez-Luque AJ, Andbjer B, Agnati LF, Fuxe K. Corticosterone strongly increases the affinity of dorsal raphe 5-HT1A receptors. Neuroreport 2004;15: 1457-1459.
165. Judge SJ, Ingram CD, Gartside SE. Moderate differences in circulating corticosterone alter receptor-mediated regulation of 5-hydroxytryptamine neuronal activity. J Psychopharmacol 2004;18: 475-483.
166. Zieglgänsberger W, French ED, Siggins GR, Bloom FE. Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons. Science 1979;205: 415-416.
167. Wagner JJ, Terman GW, Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 1993;363: 451-45.
168. Albertson TE, Joy RM, Stark LG. Modification of kindled amygdaloid seizures by opioid agonists and antagonists. J Pharmacol Exp Ther 1984;228: 620-627.
169. Cain DP, Corcoran ME. Epileptiform effects of met-enkephalin, β-endorphin and morphine: kindling of generalised seizures and potentiation of epileptiform effects by handling. Brain Res 1985;338: 327-336.
170. Tortella FC. Endogenous opioid peptides and epilepsy: quieting the seizing brain? TIPS 1988;9: 366-372.
171. Simmons ML, Chavkin C. Endogenous opioid regulation of hippocampal function. Int Rev Neurobiology 1996;39: 145-198.
172. Berman EF, Adler MW. The anticonvulsant effect of opioids and opioid peptides against maximal electroshock seizures in rats. Neuropharmacol 1984;23: 367-371.
173. Dantzer R. Cytokine, sickness behavior, and depression. Neurol Clin 2006;24: 441-460.
174. Guo JY, Li CY, Ruan YP, et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009;612: 54-60.
175. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008;32: 380-386.
176. Dunn AJ, Swiergiel AH. Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacol Biochem Behav 2005;81: 688-693.
177. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005;29: 891-909.
178. Goshen I, Yirmiya R. Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 2009;30: 30-45.
179. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem 2013;31: 761-777.
180. Parsadaniantz SM, Batsche E, Gegout-Pottie P, et al. Effects of continuous infusion of interleukin 1 beta on corticotropin-releasing hormone (CRH), CRH receptors, proopiomelanocortin gene expression and secretion of corticotropin, beta-endorphin and corticosterone. Neuroendocrinology 1997;65: 53-63.
181. Brambilla D, Franciosi S, Opp MR, Imeri L. Interleukin-1 inhibits firing of serotonergic neurons in the dorsal raphe nucleus and enhances GABAergic inhibitory post-synaptic potentials. Eur J Neurosci 2007;26: 1862-1869.
182. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011;7: 31-40.
183. Vezzani A, Aronica E, Mazarati A, Pittman QJ. Epilepsy and brain inflammation. Exp Neurol 2013;244: 11-21.
184. Librizzi L, Noe F, Vezzani A, de Curtis M, Ravizza T. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. Ann Neurol 2012;72: 82-90.
185. Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008;29: 142-160.
186. Ravizza T, Noe F, Zardoni D, Vaghi V, Sifringer M, Vezzani A. Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. Neurobiol Dis 2008;31: 327-333.
187. Noe FM, Polascheck N, Frigerio F, et al. Pharmacological blockade of IL-1beta/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiol Dis 2013;59: 183-193.
188. Dube C, Vezzani A, Behrens M, Bartfai T, Baram TZ. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol 2005;57: 152-155.
189. Viviani B, Bartesaghi S, Gardoni F, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 2003;23: 8692-8700.
190. Barbui C, Hotopf M, Garattini S. Fluoxetine dose and outcome in antidepressant drug trials. Eur J Clin Pharmacol 2002;58: 379-386.
191. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163: 1905-1917.
192. Lemonde S, Turecki G, Bakish D, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003;23: 8788-8799.
193. Pineda EA, Hensler JG, Sankar R, Shin D, Burke TF, Mazarati AM. Interleukin-1beta causes fluoxetine resistance in an animal model of epilepsy-associated depression. Neurotherapeutics 2012;9: 477-485.